2025
Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opiod use disorder in the United States
Ivasiy R, Madden L, Johnson K, Machavariani E, Ahmad B, Oliveros D, Tan J, Kil N, Altice F. Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opiod use disorder in the United States. International Journal Of Drug Policy 2025, 138: 104748. PMID: 40020306, PMCID: PMC12045481, DOI: 10.1016/j.drugpo.2025.104748.Peer-Reviewed Original ResearchConceptsOpioid use disorderSL-BUPXR-BUPUse disorderRetrospective cohort studyExtended-release buprenorphineReduce treatment discontinuationDays of supplyTreatment discontinuationSublingual buprenorphineReduce overdose riskBuprenorphine treatmentCohort studyHigh dosesPrimary outcomeImpact of dosagePatientsBuprenorphineMonthsMg/dayCommercially-insured individualsProportion of individualsOpioidOverdose riskImprove health outcomesExploration of the multi-level barriers to scaling up methadone for HIV prevention among people who inject drugs in Kazakhstan
Liberman A, Rozental Y, Ivasiy R, Kussainova A, Primbetova S, Madden L, Terlikbayeva A, Altice F. Exploration of the multi-level barriers to scaling up methadone for HIV prevention among people who inject drugs in Kazakhstan. Journal Of Substance Use And Addiction Treatment 2025, 172: 209640. PMID: 39986387, PMCID: PMC12009200, DOI: 10.1016/j.josat.2025.209640.Peer-Reviewed Original ResearchNominal group techniqueHIV preventionCommunity health workersMulti-level barriersIn-depth interviewsHealth workersPWID clientsSocioecological modelCommunity stakeholdersOpioid use disorderFocus groupsHIV epidemicClinical directorsClinical sitesEducating clientsOpioid agonist therapyImprove implementationGroup techniqueResearch teamCHWsPolicy levelUse disorderCliniciansAlternative medicationsEligibilityAssessing the comparative effectiveness of ECHO and coaching implementation strategies in a jail/provider MOUD implementation trial
Molfenter T, Vechinski J, Kim J, Zhang J, Meng L, Tveit J, Madden L, Taxman F. Assessing the comparative effectiveness of ECHO and coaching implementation strategies in a jail/provider MOUD implementation trial. Implementation Science 2025, 20: 7. PMID: 39901259, PMCID: PMC11792685, DOI: 10.1186/s13012-025-01419-6.Peer-Reviewed Original ResearchConceptsOpioid use disorderIntervention phaseMOUD useJail settingInjectable naltrexoneUse disorderImplementation strategiesCommunity Healthcare OutcomesCommunity-based partnersEffective implementation strategiesPatient countsPublic health opportunityPrevalence of opioid use disorderCommunity-based treatment providersTelementoring modelECHO sessionsTrial registry recordHealthcare outcomesImplementation trialPersistent treatment gapTreatment providersRegistry recordsHealth opportunitiesTreatment gapStudy arms
2024
Corrigendum to: Clinical characteristics associated with problematic pornography use among individuals seeking treatment for opioid use disorder
Stefanovics E, Kraus S, Madden L, Farnum S, Cannata E, Potenza M, Barry D. Corrigendum to: Clinical characteristics associated with problematic pornography use among individuals seeking treatment for opioid use disorder. Journal Of Behavioral Addictions 2024, 13: 947-948. PMID: 39714469, PMCID: PMC11737413, DOI: 10.1556/2006.2024.40000.Peer-Reviewed Original ResearchTrajectory and progress of opioid agonist therapy programs in the Kyrgyz Republic
Liberman A, Kurmanalieva A, Biibosunova D, Shumskaya N, Ivasiy R, Bromberg D, Madden L, Altice F. Trajectory and progress of opioid agonist therapy programs in the Kyrgyz Republic. Global Health Economics And Sustainability 2024, 2: 2536. PMID: 40212662, DOI: 10.36922/ghes.2536.Peer-Reviewed Original ResearchOpioid agonist therapyHuman immunodeficiency virusMortality of human immunodeficiency virusOpioid agonist therapy programsOpioid use disorderMethadone programsHIV prevention strategiesAgonist therapyImmunodeficiency virusClinical protocolsEffective treatmentUse disorderNeighboring countriesHIV preventionKyrgyz RepublicMethadoneOpioidCentral AsiaIncreased state supportCentral Asian countriesDrugCarceral systemInternational donorsLocal news coveragePolitical challengesClinical characteristics associated with problematic pornography use among individuals seeking treatment for opioid use disorder
Stefanovics E, Kraus S, Madden L, Farnum S, Cannata E, Potenza M, Barry D. Clinical characteristics associated with problematic pornography use among individuals seeking treatment for opioid use disorder. Journal Of Behavioral Addictions 2024, 13: 938-946. PMID: 39298267, PMCID: PMC11737410, DOI: 10.1556/2006.2024.00037.Peer-Reviewed Original ResearchBrief Pornography ScreenOpioid use disorderPornography useOpioid use disorder treatmentUse disorderMeasures of substance useMeasures of impulsivityProblematic pornography useMinority of individualsNegative urgencyPositive urgencyPsychotic symptomsSelf-reported dataBehavioral addictionsGambling disorderPsychiatric disordersPsychiatric symptomsSensation-seekingEmotional labilitySelf-harmSubstance useDisordersOpioidIndividualsSymptomsThe cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections
Ivasiy R, Madden L, DiDomizio E, Johnson K, Machavariani E, Ahmad B, Oliveros D, Ram A, Kil N, Altice F. The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections. Drug And Alcohol Dependence 2024, 263: 112410. PMID: 39159600, PMCID: PMC12045330, DOI: 10.1016/j.drugalcdep.2024.112410.Peer-Reviewed Original ResearchOpioid use disorderXR-NTXUse disorderHCV infectionPrescribed MOUDOpioid use disorder cascadePrevalence of opioid use disorderRetrospective cohort studyHigher treatment retentionCascade of careConcurrent infectious diseasesSix-month retentionHCV/HIV coinfectionComorbid HIVCohort studyHospital-based settingPrescribed methadoneHCVMOUD initiationHIVHCV epidemicOpioidMethadoneMOUD prescriptionsTreatment retentionA Quantitative Examination of Illness Models Among People With Opioid Use Disorder Receiving Methadone Treatment
Gazzola M, Carmichael I, Thompson E, Beitel M, Madden L, Saeed G, Hoffman K, Hammouri M, Hsaio C, Barry D. A Quantitative Examination of Illness Models Among People With Opioid Use Disorder Receiving Methadone Treatment. Journal Of Addiction Medicine 2024, 18: 262-268. PMID: 38446859, DOI: 10.1097/adm.0000000000001282.Peer-Reviewed Original ResearchBrain disease modelMethadone treatmentTreatment beliefsIllness modelAssociated with beliefsOpioid use disorderUse disorderOutpatient opioid treatment programAddiction modelTreatment programsOpioid treatment programsAddictionMethadoneMultivariate analysisScale agreementIllnessDisordersCounselingBrainBeliefsDisease modelsOpioidPatientsStatistical significanceMultivariate regressionPreferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey.
Bromberg D, Madden L, Fraenkel L, Muthulingam D, Rhoades D, Dvoriak S, Dumchev K, Pykalo I, Altice F. Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey. PLOS Global Public Health 2024, 4: e0002725. PMID: 38277422, PMCID: PMC10817130, DOI: 10.1371/journal.pgph.0002725.Peer-Reviewed Original ResearchOpioid agonist therapyWithdrawal symptomsAdverse side effectsAgonist therapySide effectsOpioid use disorderQuality-of-life improvementUse disorderCombined HIVHIV incidenceClinical decision-makingDosing frequencyRespondent-driven samplingOpioidOpioid epidemicAssess preferencesClinical concernPatient preferencesPatientsDelivery strategiesTherapyDisordersHIVPatient concernsWithdrawal
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply